Global mTOR Inhibitors Market, by Drug Type (Everomilus, Temsirolimus, Siromilus), By Indication (Oncology, Immunosuppressant, Organ Transplant, Others), by Route of Administration (Oral, Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 6,704.5 Mn in 2022, and is expected to exhibit a CAGR of 4.5% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing number of generic product launches is expected to drive the growth of global mTOR inhibitors market. For instance, in December 2019, Par Pharmaceutical, a subsidiary of Endo International plc, announced that the company has received approval from U.S. Food and Drug Administration for generic Afinitor (everolimus) 2.5 mg, 5 mg and 7.5 mg tablets.
Furthermore, initiatives to increase awareness regarding cancer and cancer treatment is expected to drive the growth of global mTOR Inhibitors market. For instance, in October 2016, Hikma Pharmaceuitcals PLC., a pharmaceutical company, launched annual breast cancer awareness campaign, it was aimed to spread knowledge on combatting the disease among the employees and the local communities in which the company operates.
Global mTOR Inhibitors Market– Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic was first reported on December 31, 2019 in Wuhan, China. The World Health Organization (WHO) declared the COVID-19 a pandemic on March 11, 2020. The pandemic caused disruptions in conducting clinical trials. This led to delay in product approvals and thereby hindered the market growth. The COVID-19 pandemic has also affected the economy by directly affecting the production and demand, creating disruptions in distribution channels, and causing a negative financial impact on companies and financial markets. The Coronavirus (COVID-19) poses an unprecedented challenge to health and epidemic prevention system, especially the healthcare of patients with cancer. According to the National Center for Biotechnology Information, a total of 161 cases of lung cancer were included in the analysis of US. As of April 15, 2020, 95 patients had delayed their return visit, and 47 cases were finally designated as having delayed admission during the epidemic and having to discontinue or delay their regular anticancer treatments. Of these 47 delayed patients, 33 were evaluated for tumor status using a computed tomography scan, six of these 33 cases (18.18%) were diagnosed as progressive disease (PD), and five cases did not return for visit. The study demonstrates the significant impact of the COVID-19 crisis on oncological care, indicating the need for appropriate change of treatment decisions and continued follow-up and psycho-oncological support during this pandemic.
Thus, impact of the Coronavirus (COVID-19) pandemic is expected to limit growth of the global mTOR Inhibitors market during the forecast period.
Browse 39 Market Data Tables and 22 Figures spread through 175 Pages and in-depth TOC on “Global mTOR Inhibitors Market”- Forecast to 2030, by Drug Type (Everomilus, Temsirolimus, Siromilus), By Indication (Oncology, Immunosuppressant, Organ Transplant, Others), by Route of Administration (Oral, Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/mtor-inhibitors-market-5019
High number of patients diagnosed with cancer is expected to drive the growth of global mTOR inhibitors Market. For instance, according to an article published by American Society of Clinical Oncology on 01 February 2022, it is estimated that more than 12,000 people in the U.S. are diagnosed with a Neuroendocrine Tumors (NET) each year, and approximately 175,000 people are living with this diagnosis. The number of people diagnosed with this type of tumor has been increasing for years.
Key Takeaways of the Global mTOR Inhibitors Market:
- The global mTOR inhibitors market is expected to exhibit a CAGR of 4.5% during the forecast period. Strong pipeline for breast cancer treatment products is expected to drive the growth of global mTOR inhibitors market. For instance, a clinical trial study sponsored by Sanofi S.A., a pharmaceutical company, for Everolimus is in clinical trial phase II.
- Among region, North America is expected to expand at the highest CAGR in the global mTOR inhibitors market over the forecast period. Increasing product launches in the North America region is expected to drive the global mTOR inhibitor market growth. For instance, in October 2021, NATCO Pharma Limited, a pharmaceutical company, announced that the company’s marketing partner Breckenridge Pharmaceutical, Inc., has launched the 10mg strength of Everolimus Tablets (generic for Afinitor) in the U.S. market.
- Major players operating in the global mTOR inhibitors market include Novartis AG, Hikma Pharmaceutical PLC., Par Pharmaceutical, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Cadilla, Pfizer, Inc., Biocon, Alkem Laboratories Ltd., Accord Healthcare Inc., Gland Pharma Ltd., Apotex Inc., and Glenmark Pharmaceuticals Ltd.
